The project for the National Key R&D Program for the "14th Five-Year Plan" led by Valgen Medtech was officially approved

Recently, Valgen Medtech Co., Ltd. (Valgen Medtech) took the lead in undertaking a product development project entitled "Development of the Dragonfly™ Transcatheter Mitral Valve Repair System"; the project was supported by Diagnostic and Therapeutic Equipment and Biomedical Material Special Subprogram under the National Key R&D Program for the "14th Five-Year Plan" In the mean time, Valgen Medtech also took part in another two projects: the "Frequently Encountered Common Diseases Control" project and the"High-end Functional and Intelligent Materials" project. Both of these projects are listed in the National Key Research and Development Program and their initiation has been approved.

Ministry of Science and Technology

Official Document of the China National Center for Biotechnology Development

Notice on Initiation of Projects for Diagnostic and Therapeutic Equipment and Biomedical Materials Special Subprogram under the National Key Research and Development Program of the Year in 2022

To all undertakers leading projects:

The initiation of projects for Diagnostic and Therapeutic Equipment and Biomedical Material Special Subprogram under the National Key Research and Development Program of the Year in 2022 has been completed; for details on the initiated projects, please refer to the Annex

73  2022YFC2409100   Development of the Dragonfly™ Transcatheter Mitral Valve Repair System   Hangzhou Valgen Medtech Co. Ltd.

The approval of Valgen Medtech's initiation of a project and the inclusion of the project in the National Key R&D Program for the "14th Five-Year Plan" demonstrates Valgen Medtech's outstanding R&D ideas and conversion capacity.Valgen Medtech is committed to finding treatment regimens for major diseases that seriously threaten human health and currently lack effective treatment methods. Valgen Medtech has become a core force in the structural heart disease intervention industry by providing patients suffering from mitral valve and tricuspid valve disease throughout the world with cutting-edge medical innovative technology and total solutions on interventional procedures.In the future, Valgen Medtech will further promote the in-depth combination of innovative technology and clinical needs in line with the strategic requirements for building China into a healthy and innovative nation in order to bring benefits to patients suffering from structural heart disease in China and the world by transforming academic achievements into clinical practices and assisting in the development of clinical studies and the output of academic achievements.

The diagnostic and therapeutic equipment and biomedical materials subprogram aims to promote a new round of science- and technology-based revolution in the health sector, focusing on major strategic diagnostic and therapeutic equipment and biomedical materials and systematically tackling bottlenecks with parts; By achieving major breakthroughs in a series of cutting-edge leading technologies, Valgen Medtech will accelerate the integration of the innovation chain, industry chain, and service chain in the Chinese medical device sector; Aiming to implement "high-end leading" technologies, Valgen Medtech will provide technological support to promote China's entire medical device industry to an internationally advanced level.

As a Chinese company, Valgen Medtech has developed a number of transcatheter valve repair devices in house and successfully overcome several bottlenecks in medical technology development in China. Valgen Medtech, as a leader in the development of structural heart disease medical technologies, has been continually making progress and developing innovative valve repair devices represented by the Dragon series of products to offer more technology options to meet clinical needs.

Valgen Medtech transcatheter products

The DragonFly™, the first transcatheter transfemoral transcatheter edge-to-edge mitral valve repair (TEER) device to be developed in house in China, has independent intellectual property rights and is protected by international patents; the development of the DragonFly™ passed the review of the Center for Medical Device Evaluation of the National Medical Products Administration (NMPA) in accordance with the Special Review Procedure for Innovative Medical Devices on March 24, 2021 and proceeded to the pre-marketing multi-center registration clinical study phase on May 4 of the same year.

At present, no Chinese mitral valve interventional procedure device has been made commercially available and such devices represent a blue ocean market to be exploited. However, Chinese TEER technologies are gradually maturing and the development of TEER technologies has entered the fast track. Valgen Medtech is likely to overtake foreign competitors, wiped out the monopoly of foreign technologies, and change China from a technology importer to a technology exporter in this field. Furthermore, Valgen Medtech will also focus on continually improving its core competitiveness, in-house innovation capacity, and technological development performance in the industry to provide technological support to promote Chinese innovative medical devices to an internationally advanced level.

Valgen Medtech

Selected as an "Eyas Program" company of Hangzhou; Selected as a National/Provincial Technology-oriented SME; Selected as a High and New Technology Company and R&D Center of Hangzhou City;

Won Second Prize in the Final Round of the China Medical Devices Design & Entrepreneurship Competition in 2018.

By January 2023, three Valgen Medtech products had passed their review in accordance with the Special Examination Procedures for Innovative Medical Devices. Three registered Class III products; One registered Class I product.

Topped the List of Chinese Unicorn Companies in 2020; ranked 8th place in the 2020-2021 Future Healthcare VB Top 100 - List of Chinese Innovative Medical Devices.

Valgen Medtech's products were shortlisted in the 2022 Outstanding Innovative Medical Devices and included in the Top 100 Innovative Medical Technology Products (Solutions) in 2022